Lost to follow-up in contemporary global cardiovascular randomized clinical trials. Robert W. Harrison, MD; Daniel Wojdyla , MS; Kenneth W. Mahaffey, MD. Duke Clinical Research Institute, Durham, NC. Results. Table 1: Study Characteristics. Table 2: Reporting of LTFU and Withdrawn Consent .
Lost to follow-up in contemporary global cardiovascular randomized clinical trials
Robert W. Harrison, MD; Daniel Wojdyla, MS; Kenneth W. Mahaffey, MD
Duke Clinical Research Institute, Durham, NC
Table 1: Study Characteristics
Table 2: Reporting of LTFU and Withdrawn Consent
Harrison, RW: None
Wojdyla, D: None
Mahaffey, KW: Consulting fees/honoraria: Johnson&Johnson, AstraZeneca, Exeter Group, Orexigan, Biotronik, Amgen, Genentech, Sun Pharma, Forest, Adolor, WebMD, Ortho/McNeill, Haemonetics, Daiichi Sankyo, Pfizer, South East Area Health Education Center, Elsevier (AHJ), Eli Lilly, Gilead Science, Bristol Myers Squibb, Glaxo Smith Kline, Novartis Pharmaceutical, Medtronic, Merck, Sanofi-Aventis, BoehringerIngleheim, Bayer, Polymedix; Research Grants: INC Research, Eli Lilly, Medtronic, Merck , Pozen, Baxter, Cordis, BoehringerIngelheim, Luitpold, AstraZeneca, Edwards Lifesciences, Bristol Myers Squibb, Abbott Vascular, Portola, Daiichi Sankyo, Sanofi, Guidant , Bayer, Amgen, Glaxo Smith Kline, Johnson & Johnson, Roche Diagnostic, Novartis Pharmaceutical, Amylin, Schering Plough Research Institute, Ikaria, The Medicines Company, Regado, Springer Publishing, KAI
Figure: Proportion of subjects with LTFU or WDC
Reference: 1FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM304755.pdf. May 23, 2012; Accessed March 1, 2013
Robert W. Harrison, MD
Duke Clinical Research Institute
2400 Pratt St.
Durham, NC 27705